Black Diamond turns down an open stretch of R&D highway, headed to a showdown with oncogenes
As one of the lead scientists involved in the development of Tarceva, David Epstein had plenty of opportunity to consider the many ways in which cancer can evade a drug and kill patients.
For the last 4 years, Epstein has been quietly working away at the problem, and he’s taken a turn down a stretch of R&D highway which he believes can lead to a full pipeline of new cancer drugs that can broach that issue for particular subsets of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.